j&j
johnson
johnson's
a
agrees
agreed
as
and
analysts
antitrust
aimed
at
also
are
artery
after
$25bn
$25.4bn
$76
guidant
giant
give
generic
deal
defibrillators
demand
detected
drug
pharmaceutical
producer
products
problems
pressure
price
pacemakers
patent
pay
pointed
&
has
heart
heartbeat
healthcare
to
technology
that
than
the
they
tubes
buy
business
because
been
battling
by
medical
mergers
meanwhile
more
move
firm
firms
fierce
for
force
fragmented
from
facing
Â£13bn
is
implant
industries
increase
irregular
it
key
keep
of
offsetting
on
out
or
overlapping
operations
open
equipment
expirations
expected
electric
each
combats
company
competition
costs
could
cut
closing
such
said
say
slowing
small
shock
share
shed
some
stent
stents
reliance
regulators
rhythm
likely
under
unblocked
us
used
number
while
which
when
widely
will
wednesday's
6%